HomeAI · summaries
Storia in 3 fonti
Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio
Cohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thirteen million dollars for NJ Bio, increasing Cohance's ownership to sixty-seven point three percent. An additional five million dollars will give Cohance a sixty-five percent stake in Aruka Bio. These transactions aim to integrate NJ Bio's services with Cohance's manufacturing capabilities. Completion of these strategic investments is expected by September twenty twenty-six.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Cohance Lifesciences invests $18 million to strengthen ADC strategy
Cohance Lifesciences will invest $18 million in NJ Bio and Aruka Bio, raising its NJ Bio stake to 67.3% and acquiring 65% of Aruka Bio.
- ·
economictimes.indiatimes.com
Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio
Cohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thirteen million dollars for NJ Bio,…
